Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia

I. Ataga, Kenneth; R. Smith, Wally; M. De Castro, Laura; Swerdlow, Paul; Saunthararajah, Yogen; Castro, Oswaldo; Vichinsky, Elliott; Kutlar, Abdullah; P. Orringer, Eugene; C. Rigdon, Greg; W. Stocker, Jonathan

doi:10.1182/blood-2007-08-110098

Public

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia

Published in Blood • Jan 12, 2008

Authors:

Kenneth I. Ataga

Wally R. Smith

Laura M. De Castro

Abstract

Senicapoc, a novel Gardos channel inhibitor, limits solute and water loss, thereby preserving sickle red blood cell (RBC) hydration. Because hemoglobin S polymerization is profoundly influenced by intracellular hemoglobin concentration, senicapoc could improve sickle RBC survival. In a 12-week, mult...

Subject

Medicine

Sickle cell anemia

Anemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!